# US 12,594,279 B2 · Composition for preventing or treating TNF-α-related disease, comprising hydroflumethiazide as active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,279 B2
- Document ID: US12594279B2
- Status: Granted
- Kind: B2
- Application number: 18/035,627
- Filed: 2021-11-05
- Published: 2023-12-28
- Granted: 2026-04-07
- Earliest claimed: 2020-11-06
- Assignees: SK Chemicals Co., Ltd.; Standigm Inc.
- Applicants: SK Chemicals Co., Ltd.; Standigm Inc.
- Inventors: Soo Min Lee; Jong-In Kim; Nam-Jin Gu; Jeong-Hoon Kim; Dae Hee Han; Hee Jung Koo
- Web page: https://patentgrep.com/patent/US12594279B2

## CPC

- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition for preventing or treating a TNF-α-related disease is disclosed. The composition includes hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient. The composition can effectively inhibit the expression or activity of TNF-α and exhibits an excellent treatment effect compared to methotrexate (MTX) or hydroxychloroquine (HCQ), which are rheumatoid arthritis treatment agents currently on the market, and, thus, can be effectively used for prevention or treatment of a TNF-α-related disease.

## Claims

### Claim 1

A method for treating a tumor necrosis factor-α (TNF-α)-related disease in a subject in need thereof, the method comprising administering, to the subject, an effective amount of a composition comprising hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient,
wherein the TNF-α-related disease is synovium proliferation, bone destruction, cartilage damage, arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, multiple sclerosis, sepsis, a respiratory disease, vasculitis, Behcet's disease, type 1 diabetes, systemic lupus erythematosus, adult-onset Still's disease, polymyositis, dermatomyositis, Wegener's granulomatosis, or a combination thereof, and
wherein the treatment of the TNF-α-related disease is delaying progress of the TNF-α-related disease, or improving or beneficially changing symptoms of the TNF-α-related disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the arthritis is rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is a food or a dietary supplement.

### Claim 4

A method of inhibiting expression or activity of tumor necrosis factor-α (TNF-α) in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 5 (depends on 4)

The method of claim 4, wherein the subject suffers from synovium proliferation, bone destruction, or cartilage damage.

### Claim 6 (depends on 4)

The method of claim 4, wherein the subject suffers from synovium proliferation, bone destruction, cartilage damage, arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, multiple sclerosis, sepsis, a respiratory disease, vasculitis, Behcet's disease, type 1 diabetes, systemic lupus erythematosus, adult-onset Still's disease, polymyositis, dermatomyositis, Wegener's granulomatosis, or a combination thereof.

### Claim 7 (depends on 4)

The method of claim 4, wherein the arthritis is rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis.

### Claim 8 (depends on 4)

The method of claim 4, wherein the composition is a food or a dietary supplement.